Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

22. Oktober 2020 16:57 ET | Quelle: Genocea Biosciences, Inc.

Genocea to Host Third Quarter 2020 Corporate Update Conference Call & Webcast

CAMBRIDGE, Mass., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, will host its third...
14. Oktober 2020 17:22 ET | Quelle: Genocea Biosciences, Inc.

Genocea Announces Upcoming Data Presentations at Virtual SITC 2020

Will showcase clinical and immune responses from the ongoing GEN-009 Phase 1/2a trial Will provide a detailed introduction to GEN-011, an adoptive T cell therapy designed to improve upon the...
22. September 2020 07:30 ET | Quelle: Genocea Biosciences, Inc.

Genocea Announces FDA Acceptance of GEN-011 IND Application

CAMBRIDGE, Mass., Sept. 22, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that...
17. September 2020 03:00 ET | Quelle: Genocea Biosciences, Inc.

Genocea Presents Follow-up Data from GEN-009 Neoantigen Vaccine Phase 1/2a Trial at ESMO Virtual Congress 2020

Step-down responses to GEN-009, with 3 objective responses (2 PR, 1 CR) in the first 5 patients, suggests added benefit to PD-1 inhibitor therapy 100% of patients have immune responses to...
03. September 2020 18:53 ET | Quelle: Genocea Biosciences, Inc.

Genocea to Present at the ESMO Virtual Congress and Two Investor Conferences in September

CAMBRIDGE, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that...
30. Juli 2020 07:00 ET | Quelle: Genocea Biosciences, Inc.

Genocea to Present Positive Preliminary Clinical Data Evaluating Neoantigen Vaccine GEN-009 in Combination with Checkpoint Inhibitors

Webcast/conference call scheduled today, July 30th at 8:00 a.m. EDT Three of five patients achieved separate RECIST responses after GEN-009 administration GEN-009 elicited antigen-specific CD4+ and...
23. Juli 2020 07:00 ET | Quelle: Genocea Biosciences, Inc.

Genocea Provides Second Quarter 2020 Corporate Update

Upcoming GEN-009 data update planned for July 30th at 8 a.m. EDTFiled IND application for GEN-011 and is working with the FDA to provide additional informationPrivate Placement with Leading Life...
22. Juli 2020 09:02 ET | Quelle: Genocea Biosciences, Inc.

Genocea Announces Private Placement Financing of Up to $80 Million

CAMBRIDGE, Mass., July 22, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today announced that it has...
20. Juli 2020 08:00 ET | Quelle: Genocea Biosciences, Inc.

Genocea Biosciences Provides Clinical Update

CAMBRIDGE, Mass., July 20, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced...
16. Juli 2020 08:00 ET | Quelle: Genocea Biosciences, Inc.

Genocea to Host Second Quarter 2020 Corporate Update Conference Call & Webcast

CAMBRIDGE, Mass., July 16, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, will host its second...

Vorherige Seite